Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.
P B Watkins, … , S A Wrighton, P S Guzelian
P B Watkins, … , S A Wrighton, P S Guzelian
Published February 1, 1989
Citation Information: J Clin Invest. 1989;83(2):688-697. https://doi.org/10.1172/JCI113933.
View: Text | PDF
Research Article Article has an altmetric score of 3

Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

  • Text
  • PDF
Abstract

The major P-450IIIA gene family member present in human liver is HLp which, like its rat liver orthologue P-450p, is inducible by glucocorticoids and catalyzes erythromycin N-demethylation. To develop a practical method to estimate the amounts of HLp in patients [14C]N-methyl erythromycin was injected into rats that had been pretreated with dexamethasone or with inducers of other forms of cytochrome P-450. The rate of demethylation of this substrate, measured simply as 14CO2 in the breath, correlated well with the concentrations of immunoreactive P-450p protein (r = 0.70), holocytochrome P-450p (r = 0.70), or with erythromycin N-demethylase activity (r = 0.90) determined in the liver microsomes prepared from each rat. Next, [14C]N-methyl erythromycin was administered to 30 patients and there was a sixfold interindividual variation in breath 14CO2 production seemingly unrelated to medications, smoking status or age. However, the average breath test values were twofold greater in female as compared to male patients (P less than 0.01). Breath 14CO2 production rose in patients retested after treatment with the P-450IIIA inducers dexamethasone (P less than 0.05) or rifampicin (P less than 0.05) and was decreased after treatment with the HLp inhibitor triacetyloleandomycin (P less than 0.05). We conclude that the erythromycin breath test provides a convenient assay of P-450IIIA cytochromes in rats and in some patients.

Authors

P B Watkins, S A Murray, L G Winkelman, D M Heuman, S A Wrighton, P S Guzelian

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 Total
Citations: 2 4 3 6 1 3 1 1 1 6 3 7 6 4 4 10 8 10 9 15 23 15 10 12 13 18 18 21 11 12 7 12 3 7 1 287
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (287)

Title and authors Publication Year
Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism.
MacLeod AK, Coquelin KS, Huertas L, Simeons FRC, Riley J, Casado P, Guijarro L, Casanueva R, Frame L, Pinto EG, Ferguson L, Duncan C, Mutter N, Shishikura Y, Henderson CJ, Cebrian D, Wolf CR, Read KD
Proceedings of the National Academy of Sciences 2024
Impact of sex and pregnancy on hepatic CYP3A4 expression and activity in a humanized mouse model
Fashe MM, Miner TA, Collazo VL, Grieco JT, Fallon JK, Jackson KD, Lee CR
Drug Metabolism and Disposition 2024
Age-related modifications in CYP-dependent drug metabolism: role of stress.
Konstandi M, Johnson EO
Frontiers in Endocrinology 2023
Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care.
Willems RAL, Michiels N, Lanting VR, Bouwense S, van den Broek BLJ, Graus M, Klok FA, Groot Koerkamp B, de Laat B, Roest M, Wilmink JW, van Es N, Mieog JSD, Ten Cate H, de Vos-Geelen J
Cancers 2023
Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine.
Jackson KD, Achour B, Lee J, Geffert RM, Beers JL, Latham BD
Drug metabolism and disposition: the biological fate of chemicals 2023
Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration.
Ohno Y, Oriyama T, Honda A, Kurokawa M, Takada T
Journal of Pharmaceutical Health Care and Sciences 2023
Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia
M Karpale, J Hukkanen, J Hakkola
Cells 2022
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.
Jacobs TG, Marzolini C, Back DJ, Burger DM
The Journal of antimicrobial chemotherapy 2022
Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers.
Shin Y, Choi C, Oh ES, Kim CO, Park K, Park MS
Drug design, development and therapy 2022
Breath Biomarkers in Diagnostic Applications
YL Pham, J Beauchamp
Molecules (Basel, Switzerland) 2021
Potential Dexamethasone–Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID?
MA Smythe, C Burns, Q Liu, CL Garwood
The Annals of pharmacotherapy 2021
Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
FT Bosch, M Candeloro, N Potere, E Porreca, MD Nisio, PW Kamphuisen
Thrombosis Research 2021
Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain
BC Agema, AW Oosten, SD Sassen, WJ Rietdijk, CC van der Rijt, BC Koch, RH Mathijssen, SL Koolen
Cancers 2021
Induced volatolomics of pathologies
F Djago, J Lange, P Poinot
Nature Reviews Chemistry 2021
Induced volatolomics of pathologies.
Djago F, Lange J, Poinot P
Nature Reviews Chemistry 2021
Inhibition and induction of CYP enzymes in humans: an update
J Hakkola, J Hukkanen, M Turpeinen, O Pelkonen
Archives of Toxicology 2020
Erlotinib treatment induces cytochrome P450 3A activity in non‐small cell lung cancer patients
A Svedberg, S Vikingsson, A Vikström, N Hornstra, M Kentson, E Branden, H Koyi, B Bergman, H Gréen
British Journal of Clinical Pharmacology 2019
Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates
D Ramsden, C Fung, N Hariparsad, JR Kenny, M Mohutsky, NJ Parrott, S Robertson, DJ Tweedie
Drug Metabolism and Disposition 2019
Inhibitory Effect of Polypodium Leucotomos Extract on Cytochrome P450 3A-mediated Midazolam Metabolism
Y GOMI, Y NISHIMURA, N KURATA, M IWASE, K SHINYA, Y KIUCHI
The Showa University Journal of Medical Sciences 2019
Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice
S Nitta, M Hashimoto, Y Kazuki, S Takehara, H Suzuki, M Oshimura, H Akita, K Chiba, K Kobayashi
The AAPS Journal 2018
Liver regeneration — mechanisms and models to clinical application
SJ Forbes, PN Newsome
Nature Reviews Gastroenterology & Hepatology 2016
Prediction of Gestational Age-Dependent Induction of In Vivo Hepatic CYP3A Activity Based on HepaRG Cells and Human Hepatocytes
Z Zhang, M Farooq, B Prasad, S Grepper, JD Unadkat
Drug metabolism and disposition: the biological fate of chemicals 2015
Comprehensive Physiology
SN Cheuvront, RW Kenefick
Comprehensive Physiology 2014
Precursors for cytochrome P450 profiling breath tests from an in silico screening approach
S Grafenstein, JE Fuchs, MM Huber, A Bassi, A Lacetera, V Ruzsanyi, J Troppmair, A Amann, KR Liedl
Journal of Breath Research 2014
Pharmacokinetic and Pharmacodynamic Drug Interactions with Ethanol (Alcohol)
LN Chan, GD Anderson
Clinical Pharmacokinetics 2014
The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis
Jiezhong Chen, Kong-Nan Zhao, Chen Chen
Annals of translational medicine 2014
Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis
TJ Velenosi, BL Urquhart
Expert Opinion on Drug Metabolism & Toxicology 2014
The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis
Jiezhong Chen, Kong-Nan Zhao, Chen Chen
Annals of translational medicine 2014
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics
AL Walker, CS Lancaster, D Finkelstein, RE Ware, A Sparreboom
American journal of physiology. Cell physiology 2013
Breath Tests to Phenotype Drug Disposition in Oncology
FL Opdam, AS Modak, H Gelderblom, HJ Guchelaar
Clinical Pharmacokinetics 2013
Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy
GT Everson, JC Hoefs, CU Niemann, KM Olthoff, R Dupuis, S Lauriski, A Herman, N Milne, BW Gillespie, NP Goodrich, JE Everhart
Liver Transplantation 2013
OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition
CS Lancaster, GH Bruun, CJ Peer, TS Mikkelsen, TJ Corydon, AA Gibson, S Hu, SJ Orwick, RH Mathijssen, WD Figg, SD Baker, A Sparreboom
Clinical Pharmacology & Therapeutics 2012
Phenotyping drug disposition in oncology
FL Opdam, H Gelderblom, HJ Guchelaar
Cancer Treatment Reviews 2012
Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats : GENDER DIFFERENCES IN PK OF LUMEFANTRINE
SP Singh, GK Jain
Biopharmaceutics & Drug Disposition 2012
Pharmacokinetics and Pharmacodynamic Changes Associated with Aging and Implications for Drug Therapy
LC Sera, ML McPherson
Clinics in Geriatric Medicine 2012
Induction of cytochrome P450 enzymes: a view on human in vivo findings
J Hukkanen
Expert Review of Clinical Pharmacology 2012
The Handbook of Metabolomics
TW Fan, AN Lane, RM Higashi
2012
Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4
HJ Burt, H Pertinez, C Säll, C Collins, R Hyland, JB Houston, A Galetin
Drug Metabolism and Disposition 2012
Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism
RM Franke, CS Lancaster, CJ Peer, AA Gibson, AM Kosloske, SJ Orwick, RH Mathijssen, WD Figg, SD Baker, A Sparreboom
Clinical Pharmacology & Therapeutics 2011
The use of 13C-erythromycin as an in vivo probe to evaluate CYP3A-mediated drug interactions in rats
E Sugiyama, A Kikuchi, M Inada, H Sato
Journal of Pharmaceutical Sciences 2011
Direct radiocarbon analysis of exhaled air
T Schulze-König, L Wacker, HA Synal
Journal of Analytical Atomic Spectrometry 2011
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test
M Michael, C Cullinane, A Hatzimihalis, C O’Kane, A Milner, R Booth, S Schlicht, SJ Clarke, P Francis
Cancer Chemotherapy and Pharmacology 2011
In Vivo Inhibition of CYP3A-Mediated Midazolam Metabolism by Anchusan in Rats
Y Saito, Y Nishimura, N Kurata, M Iwase, K Aoki, H Yasuhara
Journal of Pharmacological Sciences 2011
Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects
SE Shoaf, P Bricmont, S Mallikaarjun
British Journal of Clinical Pharmacology 2011
Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant
SA Stoch, C Gargano, J Valentine, MP Braun, MG Murphy, M Fedgchin, A Majumdar, E Pequignot, KM Gottesdiener, KJ Petty, D Panebianco, D Dean, WK Kraft, HE Greenberg
Cancer Chemotherapy and Pharmacology 2010
Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?
C Kirwan, I MacPhee, B Philips
Expert Opinion on Drug Metabolism & Toxicology 2010
A highly sensitive SPE- liquid/liquid extraction – RPLC analytical method for the determination of 6β-hydroxycortisol and cortisol in cancer patients' urine
Z Hong, F Yu, L Ying, L Aibin
Journal of Medical Colleges of PLA 2010
Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids
Z Dvorak, P Pavek
Drug Metabolism Reviews 2010
Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism
MC Sangar, HK Anandatheerthavarada, W Tang, SK Prabu, MV Martin, M Dostalek, FP Guengerich, NG Avadhani
The FEBS journal 2009
Challenges for drug studies in children: CYP3A phenotyping as example
SN de Wildt, S Ito, G Koren
Drug Discovery Today 2009
Safety testing of metabolites: Expectations and outcomes
KS Pang
Chemico-Biological Interactions 2009
The Drug Transporter−Metabolism Alliance: Uncovering and Defining the Interplay
LZ Benet
Molecular Pharmaceutics 2009
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics
B Zhang, W Xie, MD Krasowski
Pharmacogenomics 2008
Reply
J Bommer, T Heinrich, H Heidt, V Hafner, E Jenetzky, I Walter-Sack, G Mikus
Nephrology Dialysis Transplantation 2008
Inhibition and induction of human cytochrome P450 enzymes: current status
O Pelkonen, M Turpeinen, J Hakkola, P Honkakoski, J Hukkanen, H Raunio
Archives of Toxicology 2008
Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice
PO Gubbins, BJ Gurley, DK Williams, SR Penzak, SA McConnell, AM Franks, M Saccente
European Journal of Clinical Pharmacology 2008
Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes
RM Franke, SD Baker, RH Mathijssen, EG Schuetz, A Sparreboom
Clinical Pharmacology & Therapeutics 2008
A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy
JS Graham, S Falk, LM Samuel, JM Cendros, TR Evans
Cancer Chemotherapy and Pharmacology 2008
In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: A comparison with human liver microsomes
L Quintieri, M Fantin, P Palatini, SD Martin, A Rosato, M Caruso, C Geroni, M Floreani
Biochemical Pharmacology 2008
The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans
PJ Roberts, KD Rollins, AD Kashuba, MF Paine, AC Nelsen, EE Williams, C Moran, JK Lamba, EG Schuetz, RL Hawke
Drug Metabolism and Disposition 2008
Forkhead Box A2–Mediated Regulation of Female-Predominant Expression of the Mouse Cyp2b9 Gene
T Hashita, T Sakuma, M Akada, A Nakajima, H Yamahara, S Ito, H Takesako, N Nemoto
Drug Metabolism and Disposition 2008
Synergism of Glucocorticoid Hormone with Growth Hormone for Female-Specific Mouse Cyp3a44 Gene Expression
T Sakuma, W Bhadhprasit, T Hashita, N Nemoto
Drug Metabolism and Disposition 2008
Novel Single Nucleotide Polymorphisms in the Promoter and Intron 1 of Human Pregnane X Receptor/NR1I2 and Their Association with CYP3A4 Expression
J Lamba, V Lamba, S Strom, R Venkataramanan, E Schuetz
Drug Metabolism and Disposition 2007
Cytochrome P4503Apolymorphisms and immunosuppressive drugs: an update
D Anglicheau, C Legendre, P Beaune, E Thervet
Pharmacogenomics 2007
Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results
LA Frassetto, S Poon, C Tsourounis, C Valera, LZ Benet
Clinical Pharmacology & Therapeutics 2007
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma
R Chugh, T Wagner, KA Griffith, JM Taylor, DG Thomas, FP Worden, KM Leu, MM Zalupski, LH Baker
Cancer 2007
Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes
M Schirmer, A Rosenberger, K Klein, B Kulle, MR Toliat, P Nürnberg, UM Zanger, L Wojnowski
Pharmacogenomics 2007
In vivoEffect of I'm-Yunity™ on Hepatic Cytochrome P450 3A4
JP Nicandro, C Tsourounis, L Frassetto, BJ Guglielmo
Journal of Herbal Pharmacotherapy 2007
Side Effects of Drugs Annual
T Vial, J Descotes, F Braun, M Behrend
Side Effects of Drugs Annual 2007
Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized Mice
MA Felmlee, HK Lon, FJ Gonzalez, AM Yu
Drug Metabolism and Disposition 2007
Cytochrome P450 4F subfamily: At the crossroads of eicosanoid and drug metabolism
A Kalsotra, HW Strobel
Pharmacology & Therapeutics 2006
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients
S Mouly, N Rizzo-Padoin, G Simoneau, C Verstuyft, G Aymard, C Salvat, I Mahé, JF Bergmann
British Journal of Clinical Pharmacology 2006
Evidence for cytochrome P450 3A expression and catalytic activity in rat blood lymphocytes
A Dey, S Yadav, A Dhawan, PK Seth, D Parmar
Life Sciences 2006
The Influence of Granisetron on the Pharmacokinetics and Pharmacodynamics of Docetaxel in Asian Lung Cancer Patients
M Miyata, K Yasuda, N Burioka, H Takane, H Suyama, Y Shigeoka, M Endo, J Kurai, M Morita, T Igishi, E Shimizu
The Cancer Journal 2006
Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment
RH Mathijssen, RH van Schaik
European Journal of Cancer 2006
Paediatric Clinical Pharmacology
T Johnson
Paediatric Clinical Pharmacology: A Subtle Compromise 2006
Noninvasive Evaluation of Liver Disease Severity
JC Hoefs, PT Chen, P Lizotte
Clinics in Liver Disease 2006
Role of Protein Kinase C-mediated Protein Phosphorylation in Mitochondrial Translocation of Mouse CYP1A1, Which Contains a Non-canonical Targeting Signal
VR Dasari, HK Anandatheerthavarada, MA Robin, E Boopathi, G Biswas, JK Fang, DW Nebert, NG Avadhani
The Journal of biological chemistry 2006
Growth Hormone Regulation of Sex-Dependent Liver Gene Expression
DJ Waxman, C OConnor
Molecular Endocrinology 2006
Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor
J Chen, K Raymond
Annals of clinical microbiology and antimicrobials 2006
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4
S Zhou, E Chan, X Li, M Huang
Therapeutics and Clinical Risk Management 2005
Effect of Chronic Administration of Ritonavir on Function of Cytochrome P450 3A and P-Glycoprotein in Rats
M Kageyama, H Namiki, H Fukushima, S Terasaka, T Togawa, A Tanaka, Y Ito, N Shibata, K Takada
Biological & Pharmaceutical Bulletin 2005
Gender Differences in the Pharmacokinetics of Oral Dermatologic Medications
DJ Fife, HI Maibach
Cutaneous and Ocular Toxicology 2005
Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levels
D Festi, S Capodicasa, L Sandri, L Colaiocco-Ferrante, T Staniscia, E Vitacolonna, A Vestito, P Simoni, G Mazzella, P Portincasa, E Roda, A Colecchia
World journal of gastroenterology : WJG 2005
Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: Comparison with Child-Pugh score and serum bile acid levels
D Festi
World journal of gastroenterology : WJG 2005
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs:
S Zhou, SY Chan, BC Goh, E Chan, W Duan, M Huang, HL McLeod
Clinical Pharmacokinetics 2005
Cytochrome P450
PR de Montellano
Cytochrome P450 2005
METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION?
C Tang, JH Lin, AY Lu
Drug Metabolism and Disposition 2005
Growth Hormone Determines Sexual Dimorphism of Hepatic Cytochrome P450 3A4 Expression in Transgenic Mice
C Cheung, AM Yu, CS Chen, KW Krausz, LG Byrd, L Feigenbaum, RJ Edwards, DJ Waxman, FJ Gonzalez
The Journal of pharmacology and experimental therapeutics 2005
Population pharmacokinetics of weekly docetaxel in patients with advanced cancer
KA Slaviero, SJ Clarke, AJ McLachlan, EY Blair, LP Rivory
British Journal of Clinical Pharmacology 2004
Suppression of female-specific murine Cyp2b9 gene expression by growth or glucocorticoid hormones
T Sakuma, K Kitajima, M Nishiyama, M Mashino, T Hashita, N Nemoto
Biochemical and Biophysical Research Communications 2004
Within-person variability of urinary 6β-hydroxycortisol to urinaryl ratios in Caucasian women
Z Chen, LA Dunning, KE Anderson, JL Holtzman, W Zheng
Steroids 2004
Collaborated regulation of female-specific murine Cyp3a41 gene expression by growth and glucocorticoid hormones
T Sakuma, K Kitajima, M Nishiyama, Y Endo, K Miyauchi, K Jarukamjorn, N Nemoto
Biochemical and Biophysical Research Communications 2004
Effects of growth hormone deficiency and rhGH replacement therapy on the 6?-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children
B Sinu�s, E Mayayo, A Fanlo, E Mayayo, ML Bernal, P Bocos, E Bello, JI Labarta, A Ferr�ndez-Long�s
European Journal of Clinical Pharmacology 2004
Ethnic Differences in Genetic Polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1
S OZAWA, A SOYAMA, M SAEKI, H FUKUSHIMA-UESAKA, M ITODA, S KOYANO, K SAI, Y OHNO, Y SAITO, J SAWADA
Drug Metabolism and Pharmacokinetics 2004
Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
RH Mathijssen, FA de Jong, RH van Schaik, ER Lepper, LE Friberg, T Rietveld, P Bruijn, WJ Graveland, WD Figg, J Verweij, A Sparreboom
JNCI Journal of the National Cancer Institute 2004
The Effects of Modifying In Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity
NG Agrawal, CZ Matthews, RS Mazenko, EJ Woolf, AG Porras, X Chen, JL Miller, N Michiels, M Wehling, A Schultz, AB Gottlieb, WK Kraft, HE Greenberg, SA Waldman, SP Curtis, KM Gottesdiener
The Journal of Clinical Pharmacology 2004
Principles of Gender-Specific Medicine
G Supinski, LA Callahan
Principles of Gender-Specific Medicine 2004
Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats
H Konishi, M Sumi, T Minouchi, A Yamaji, M Sumi, N Shibata, K Takada
Journal of Pharmacy and Pharmacology 2004
Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis Volume 3
DZ DArgenio
2004
Aging Biology and Geriatric Clinical Pharmacology
AJ McLean, DG Couteur
Pharmacological reviews 2004
The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes
JM Reid, DL Walker, JK Miller, LM Benson, AJ Tomlinson, S Naylor, AL Blajeski, PM LoRusso, MM Ames
Clinical cancer research 2004
Cytochrome P450 3A and their regulation
O Burk, L Wojnowski
Naunyn-Schmiedeberg's Archives of Pharmacology 2004
Effects of growth hormone deficiency and rhGH replacement therapy on the 6?-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children
B Sinus, E Mayayo, A Fanlo, E Mayayo, ML Bernal, P Bocos, E Bello, JI Labarta, A Ferrndez-Longs
European Journal of Clinical Pharmacology 2004
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients
HS Lee, BC Goh, L Fan, YM Khoo, L Wang, R Lim, AB Ong, C Chua
British Journal of Clinical Pharmacology 2003
Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women
MD Floyd, G Gervasini, AL Masica, G Mayo, AL George, K Bhat, RB Kim, GR Wilkinson
Pharmacogenetics 2003
Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy
KA Slaviero, SJ Clarke, LP Rivory
The Lancet Oncology 2003
Two CCAAT/enhancer binding protein sites in the cytochrome P4503A1 locus. Potencial role in the glucocorticoid response
E Rodrigues, MJ Vilarem, V Ribeiro, P Maurel, MC Lechner
European Journal of Biochemistry 2003
Gender-Specific Implications for Cardiovascular Medication Use in the Elderly
JB Schwartz
Cardiology in Review 2003
Sex is a major determinant of CYP3A4 expression in human liver
R Wolbold, K Klein, O Burk, AK Nüssler, P Neuhaus, M Eichelbaum, M Schwab, UM Zanger
Hepatology 2003
Cytochrome P450 3A4 activity after surgical stress
CE Haas, DC Kaufman, CE Jones, AH Burstein, W Reiss
Critical Care Medicine 2003
The [14C-N-methyl]-erythromycin breath test dosimetry complies with the French regulations for radiation safety
C Salvat, S Mouly, N Rizzo-Padoin, AL Knellwolf, G Simoneau, M Duet, V Nataf, O Bailliart, JF Bergmann
Fundamental & Clinical Pharmacology 2003
Single-point plasma or urine dextromethorphan method for determining CYP3A activity
BP Kuo, OY Hu, CH Hsiong, LH Pao, TS Chen, CF Hung
Biopharmaceutics & Drug Disposition 2003
An inter- and intra-laboratory comparison of breath13CO2analysis
F Perri, RM Zagari, JS Uebersax, M Quitadamo, F Bazzoli
Alimentary Pharmacology & Therapeutics 2003
Drugs and the Pharmaceutical Sciences
D Thompson
Drugs and the Pharmaceutical Sciences 2003
In vivo activation of the human CYP3A4 promoter in mouse liver and regulation by pregnane X receptors
W Zhang, A Purchio, K Chen, SM Burns, CH Contag, PR Contag
Biochemical Pharmacology 2003
Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development
K Bachmann, S Wrighton, B Ring
Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development 2003
Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man
RA Mirghani, Ö Ericsson, G Tybring, LL Gustafsson, L Bertilsson
European Journal of Clinical Pharmacology 2003
Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [ 14 C]erythromycin breath and urine test
WP Lemahieu, BD Maes, Y Ghoos, P Rutgeerts, K Verbeke, Y Vanrenterghem
AJP Gastrointestinal and Liver Physiology 2003
The Influence of Sex on Pharmacokinetics:
JB Schwartz
Clinical Pharmacokinetics 2003
Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism: Focus On In Vitro Studies
MT Donato, JV Castell
Clinical Pharmacokinetics 2003
Troglitazone Induces CYP3A4 Activity Leading to Falsely Abnormal Dexamethasone Suppression Test
EV Dimaraki, CA Jaffe
The Journal of clinical endocrinology and metabolism 2003
MODELING OF INTESTINAL DRUG ABSORPTION: ROLES OF TRANSPORTERS AND METABOLIC ENZYMES (FOR THE GILLETTE REVIEW SERIES)
KS Pang
Drug Metabolism and Disposition 2003
A TRANSGENIC MOUSE MODEL WITH A LUCIFERASE REPORTER FOR STUDYING IN VIVO TRANSCRIPTIONAL REGULATION OF THE HUMAN CYP3A4 GENE
W Zhang, AF Purchio, K Chen, J Wu, L Lu, R Coffee, PR Contag, DB West
Drug Metabolism and Disposition 2003
PHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19
BN Yu, GL Chen, N He, DS Ouyang, XP Chen, ZQ Liu, HH Zhou
Drug Metabolism and Disposition 2003
Transgenic Mouse Models of Human CYP3A4 Gene Regulation
GR Robertson, J Field, B Goodwin, S Bierach, M Tran, A Lehnert, C Liddle
Molecular pharmacology 2003
Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals
MM Galteau, F Shamsa
European Journal of Clinical Pharmacology 2003
Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans
CA Jaffe, DK Turgeon, K Lown, R Demott-Friberg, PB Watkins
American journal of physiology. Endocrinology and metabolism 2002
Breath testing for human liver function assessment
A Armuzzi, M Candelli, MA Zocco, A Andreoli, AD Lorenzo, EC Nista, L Miele, F Cremonini, IA Cazzato, A Grieco, G Gasbarrini, A Gasbarrini
Alimentary Pharmacology & Therapeutics 2002
Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
S Wanwimolruk, MF Paine, SN Pusek, PB Watkins
British Journal of Clinical Pharmacology 2002
Sex and age differences in the pharmacokinetics of alosetron
KM Koch, JL Palmer, N Noordin, JJ Tomlinson, C Baidoo
British Journal of Clinical Pharmacology 2002
REGULATION OFCYP3AGENETRANSCRIPTION BY THEPREGNANEX RECEPTOR*
B Goodwin, MR Redinbo, SA Kliewer
Annual Review of Pharmacology and Toxicology 2002
Identification of the novel splicing variants for the hPXR in human livers
S Fukuen, T Fukuda, H Matsuda, A Sumida, I Yamamoto, T Inaba, J Azuma
Biochemical and Biophysical Research Communications 2002
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer
AB Spurdle, B Goodwin, E Hodgson, JL Hopper, X Chen, DM Purdie, MR McCredie, GG Giles, G Chenevix-Trench, C Liddle
Pharmacogenetics 2002
A Wide Interindividual Variability of Urinary 6β-Hydroxycortisol to Free Cortisol in 487 Healthy Japanese Subjects in Near Basal Condition
K Inagaki, M Inagaki, T Kataoka, I Sekido, MA Gill, M Nishida
Therapeutic Drug Monitoring 2002
The interaction of medications used in palliative care
SA Bernard
Hematology/Oncology Clinics of North America 2002
Application of Isotopic Ratio Mass Spectrometry for the in Vitro Determination of Demethylation Activity in Human Liver Microsomes Using N-methyl-13C-Labeled Substrates
F Grand, I Kilinc, A Sarkis, J Guitton
Analytical Biochemistry 2002
Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man
GG Gibson, NJ Plant, KE Swales, A Ayrton, W El-Sankary
Xenobiotica 2002
Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response
LP Rivory, KA Slaviero, SJ Clarke
British Journal of Cancer 2002
Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping Strategies
BC Goh, SC Lee, LZ Wang, L Fan, JY Guo, J Lamba, E Schuetz, R Lim, HL Lim, AB Ong, HS Lee
Journal of Clinical Oncology 2002
Genotyping and Phenotyping the Cytochrome P-450 Enzymes:
KA Bachmann
American Journal of Therapeutics 2002
The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism
SA Kliewer, B Goodwin, TM Willson
Endocrine reviews 2002
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants
J Zhang, P Kuehl, ED Green, JW Touchman, PB Watkins, A Daly, SD Hall, P Maurel, M Relling, C Brimer, K Yasuda, SA Wrighton, M Hancock, RB Kim, S Strom, K Thummel, CG Russell, JR Hudson, EG Schuetz, MS Boguski
Pharmacogenetics 2001
Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers
Y Khaliq, K Gallicano, C Tisdale, G Carignan, C Cooper, A McCarthy
British Journal of Clinical Pharmacology 2001
Evolutionarily divergent electron donor proteins interact with P450MT2 through the same helical domain but different contact points
HK Anandatheerthavarada, G Amuthan, G Biswas, MA Robin, R Murali, MR Waterman, NG Avadhani
The EMBO Journal 2001
Active secretion and enterocytic drug metabolism barriers to drug absorption1PII of original article: S0169-409X(96)003304. The article was originally published in Advanced Drug Delivery Reviews 20 (1996) 99–112.1
VJ Wacher, L Salphati, LZ Benet
Advanced Drug Delivery Reviews 2001
Effect of influenza immunization on CYP3A4 activity
MS Hayney, RJ Hammes, JP Fine, JA Bianco
Vaccine 2001
Effects of Metronidazole on Hepatic CYP3A4 Activity
CE Haas, DC Kaufman, RC DiCenzo
Pharmacotherapy 2001
Race but Not Age Affects Erythromycin Breath Test Results in Older Hypertensive Men
JB Schwartz
The Journal of Clinical Pharmacology 2001
Assessment of drug-drug interactions: concepts and approaches
RJ Weaver
Xenobiotica 2001
SEX AND ETHNICITY MAY CHIEFLY INFLUENCE THE INTERACTION OF FLUCONAZOLE WITH CALCINEURIN INHIBITORS12:
AS Mathis, T DiRenzo, GS Friedman, B Kaplan, R Adamson
Transplantation 2001
The Erythromycin Breath Test For the Prediction of Drug Clearance:
LP Rivory, KA Slaviero, JM Hoskins, SJ Clarke
Clinical Pharmacokinetics 2001
Mdr1 Limits CYP3A Metabolism in Vivo
LB Lan, JT Dalton, EG Schuetz
Molecular pharmacology 2000
Quantitative RT-PCR for CYP3A4 mRNA in human peripheral lymphocytes: induction of CYP3A4 in lymphocytes and in liver by rifampicin
T Nakamoto, I Hase, S Imaoka, T Hiroi, Y Oda, A Asada, Y Funae
Pharmacogenetics 2000
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes
DS Streetman, JS Bertino, AN Nafziger
Pharmacogenetics 2000
Variability in Activity of Hepatic CYP3A4 in Patients Infected with HIV
D Slain, A Pakyz, DS Israel, S Monroe, RE Polk
Pharmacotherapy 2000
Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis
MC Bastien, F Leblond, V Pichette, JP Villeneuve
Canadian Journal of Physiology and Pharmacology 2000
Can oral midazolam predict oral cyclosporine disposition?
MF Paine, CL Davis, DD Shen, CL Marsh, VA Raisys, KE Thummel
European Journal of Pharmaceutical Sciences 2000
Gender-Specific Effects on Verapamil Pharmacokinetics and Pharmacodynamics in Humans
ME Krecic-Shepard, CR Barnas, J Slimko, MP Jones, JB Schwartz
The Journal of Clinical Pharmacology 2000
Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up
V Meunier, M Bourrie, B Julian, E Marti, F Guillou, Y Berger, G Fabre
Xenobiotica 2000
Correlation Between Docetaxel Clearance and Estimated Cytochrome P450 Activity by Urinary Metabolite of Exogenous Cortisol
N Yamamoto, T Tamura, Y Kamiya, I Sekine, H Kunitoh, N Saijo
Journal of Clinical Oncology 2000
Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000
CA Felix, BJ Lange, JM Chessells
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2000
Low Intraindividual Variability of Cyclosporin A Exposure Reduces Chronic Rejection Incidence and Health Care Costs
BD Kahan, M Welsh, DL Urbauer, MB Mosheim, KM Beusterien, MR Wood, LP Schoenberg, J Dicesare, SM Katz, CT Buren
Journal of the American Society of Nephrology : JASN 2000
Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation
M M Doherty, K S Pang
Pharmaceutical Research 2000
Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers
RJ Fontana, KS Lown, MF Paine, L Fortlage, RM Santella, JS Felton, MG Knize, A Greenberg, PB Watkins
Gastroenterology 1999
Effects of Chronic Administration of Glucocorticoid on Midazolam Pharmacokinetics in Humans
M Nakajima, T Suzuki, T Sasaki, T Yokoi, A Hosoyamada, T Yamamoto, Y Kuroiwa
Therapeutic Drug Monitoring 1999
Rifampicin Treatment Greatly Increases the Apparent Oral Clearance of Qninidine
P Damkier, LL Hansen, K Brøsen
Pharmacology & Toxicology 1999
Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine
P Damkier, LL Hansen, K Brosen
British Journal of Clinical Pharmacology 1999
Correlation Between Pretransplantation Test Dose Cyclosporine Pharmacokinetic Profiles and Posttransplantation Sirolimus Blood Levels in Renal Transplant Recipients
B Kaplan, HU Meier-Kriesche, KL Napoli, BD Kahan
Therapeutic Drug Monitoring 1999
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A*
MT Kinirons, D O'Shea, RB Kim, JD Groopman, KE Thummel, AJ Wood, GR Wilkinson
Clinical Pharmacology & Therapeutics 1999
Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity
J McCrea, T Prueksaritanont, BJ Gertz, A Carides, L Gillen, S Antonello, MJ Brucker, C Miller-Stein, B Osborne, S Waldman
The Journal of Clinical Pharmacology 1999
Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers
MF Hebert, RM Fisher, CL Marsh, D Dressler, I Bekersky
The Journal of Clinical Pharmacology 1999
Physiological Role of the N-terminal Processed P4501A1 Targeted to Mitochondria in Erythromycin Metabolism and Reversal of Erythromycin-mediated Inhibition of Mitochondrial Protein Synthesis
HK Anandatheerthavarada, C Vijayasarathy, SV Bhagwat, G Biswas, J Mullick, NG Avadhani
The Journal of biological chemistry 1999
Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration
A E Muñoz, C Miguez, M Rubio, M Bartellini, D Levi, A Podestá, V Niselman, R Terg
Digestive Diseases and Sciences 1999
Cytochrome P450 3A: Ontogeny and Drug Disposition
SN de Wildt, GL Kearns, JS Leeder, JN van den Anker
Clinical Pharmacokinetics 1999
Effects of CYP3A Inhibition on the Metabolism of Cilostazol:
A Suri, WP Forbes, SL Bramer
Clinical Pharmacokinetics 1999
Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment
P Glue, R P Clement
Cellular and Molecular Neurobiology 1999
Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease
E Tanaka
Journal of Clinical Pharmacy and Therapeutics 1998
Effect of CYP3A inhibition on vesnarinone metabolism in humans*
C Wandel, CC Lang, DC Cowart, AF Girard, S Bramer, DA Flockhart, AJ Wood
Clinical Pharmacology & Therapeutics 1998
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin*
JC Gorski, DR Jones, BD Haehner-Daniels, MA Hamman, EM O'Mara, SD Hall
Clinical Pharmacology & Therapeutics 1998
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
KE Thummel, GR Wilkinson
Annual Review of Pharmacology and Toxicology 1998
Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction
MF Fromm, K Dilger, D Busse, HK Kroemer, M Eichelbaum, U Klotz
British Journal of Clinical Pharmacology 1998
SXR, a novel steroid and xenobiotic-sensing nuclear receptor
B Blumberg, W Sabbagh, H Juguilon, J Bolado, CM van Meter, ES Ong, RM Evans
Genes & development 1998
A qualitative method for assessing the14C labelling position in [14C]-dimethyl aminoantipyrine (aminopyrine)
P Levêque, B Gallez
Journal of Labelled Compounds and Radiopharmaceuticals 1998
Disposition of 14C-eptifibatide after intravenous administration to healthy men
KB Alton, T Kosoglou, S Baker, MB Affrime, MN Cayen, JE Patrick
Clinical Therapeutics 1998
Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam*
AD Kashuba, JS Bertino, ML Rocci, RW Kulawy, DJ Beck, AN Nafziger
Clinical Pharmacology & Therapeutics 1998
Selective effects of somatostatin analogs on human drug-metabolizing enzymes*
E Rasmussen, B Eriksson, K Öberg, U Bondesson, A Rane
Clinical Pharmacology & Therapeutics 1998
Respective Roles of Human Cytochrome P-4502E1, 1A2, and 3A4 in the Hepatic Microsomal Ethanol Oxidizing System
KS Salmela, IG Kessova, IB Tsyrlov, CS Lieber
Alcoholism, clinical and experimental research 1998
Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats
M Watanabe, T Tateishi, M Asoh, H Nakura, M Tanaka, T Kumai, S Kobayashi
Life Sciences 1998
HumanMDR1and Mousemdr1aP-Glycoprotein Alter the Cellular Retention and Disposition of Erythromycin, but Not of Retinoic Acid or Benzo(a)pyrene
EG Schuetz, K Yasuda, K Arimori, JD Schuetz
Archives of Biochemistry and Biophysics 1998
Effect of Multiple Doses of Rifampin on the [ 14 C N -methyl] Erythromycin Breath Test in Healthy Male Volunteers
MN Gharaibeh, LP Gillen, B Osborne, JI Schwartz, SA Waldman
The Journal of Clinical Pharmacology 1998
Cytochromes P450 in crustacea
MO James, SM Boyle
Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology 1998
Identification of cytochrome P450 isozymes involved in metabolism of the α 1 -adrenoceptor blocker tamsulosin in human liver microsomes
H KAMIMURA, S OISHIOE, H MATSUSHIMA, T WATANABE, S HIGUCHI, M HALL, SG Wood, LF Chasseaud
Xenobiotica 1998
Metabolic capacities in cultured human hepatocytes obtained by a new isolating procedure from non-wedge small liver biopsies
P David, C Viollon, E Alexandre, A Azimzadeh, L Nicod, P Wolf, D Jaeck, K Boudjema, L Richert
Human & Experimental Toxicology 1998
Environmental Xenobiotics and the Antihormones Cyproterone Acetate and Spironolactone Use the Nuclear Hormone Pregnenolone X Receptor to Activate the CYP3A23 Hormone Response Element
EG Schuetz, C Brimer, JD Schuetz
Molecular pharmacology 1998
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
KS Lown, DG Bailey, RJ Fontana, SK Janardan, CH Adair, LA Fortlage, MB Brown, W Guo, PB Watkins
Journal of Clinical Investigation 1997
Dietary salt increases first-pass elimination of oral quinidine*
D Darbar, S Dell'Orto, K Mörike, GR Wilkinson, DM Roden
Clinical Pharmacology & Therapeutics 1997
Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
M Hebert
Advanced Drug Delivery Reviews 1997
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*
KS Lown, RR Mayo, AB Leichtman, H Hsiao, DK Turgeon, P Schmiedlin-Ren, MB Brown, W Guo, SJ Rossi, LZ Benet, PB Watkins
Clinical Pharmacology & Therapeutics 1997
Assessment of Cytochrome P450 3A4 Activity during the Menstrual Cycle Using Alfentanil as a Noninvasive Probe
ED Kharasch, M Russell, K Garton, G Lentz, TA Bowdle, K Cox
Anesthesiology 1997
Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents*
E Iatsimirskaia, S Tulebaev, E Storozhuk, I Utkin, D Smith, N Gerber, T Koudriakova
Clinical Pharmacology & Therapeutics 1997
Predicting Drug Interactions In Vivo from Experiments In Vitro
CA Jamis-Dow, ML Pearl, PB Watkins, DS Blake, RW Klecker, JM Collins
American Journal of Clinical Oncology 1997
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test *
CL Cheng, DE Smith, PL Carver, SR Cox, PB Watkins, DS Blake, CA Kauffman, KM Meyer, GL Amidon, PL Stetson
Clinical Pharmacology & Therapeutics 1997
Localization of Multiple Forms of Inducible Cytochromes P450 in Rat Liver Mitochondria: Immunological Characteristics and Patterns of Xenobiotic Substrate Metabolism
HK Anandatheerthavarada, S Addya, RS Dwivedi, G Biswas, J Mullick, NG Avadhani
Archives of Biochemistry and Biophysics 1997
Use of Probe Drugs as Predictors of Drug Metabolism in Humans
KT Kivistö, HK Kroemer
The Journal of Clinical Pharmacology 1997
In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin
RJ Riley, D Howbrook
Journal of Pharmacological and Toxicological Methods 1997
Do Endogenous Volatile Organic Chemicals Measured in Breath Reflect and Maintain CYP2E1 Levelsin Vivo?
JM Mathews, JH Raymer, AS Etheridge, GR Velez, JR Bucher
Toxicology and Applied Pharmacology 1997
Genetic Polymorphisms in Human Drug-Metabolizing Enzymes: Potential Uses of Reverse Genetics to Identify Genes of Toxicological Relevance
A Puga, DW Nebert, RA McKinnon, AG Menon
Critical Reviews in Toxicology 1997
Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells
L Nicod, C Viollon, A Regnier, A Jacqueson, L Richert
Human & Experimental Toxicology 1997
Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function
MG Sturgill, GH Lambert
Clinical chemistry 1997
Assessment of monoethylglycinexylidide as measure of liver function for patients with chronic viral hepatitis
RJ Elin, MW Fried, M Sampson, M Ruddel, DE Kleiner, AM DiBisceglie
Clinical chemistry 1997
Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency
MW Linder, RA Prough, R Valdes
Clinical chemistry 1997
Pharmacokinetic Optimisation of Cancer Chemotherapy: Effect on Outcomes
E Masson, WC Zamboni
Clinical Pharmacokinetics 1997
Erythromycin Breath Test and Clinical Transplantation
PB Watkins
Therapeutic Drug Monitoring 1996
Active secretion and enterocytic drug metabolism barriers to drug absorption
VJ Wacher, L Salphati, LZ Benet
Advanced Drug Delivery Reviews 1996
Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice*
DG Bailey, JR Bend, JM Arnold, LT Tran, JD Spence
Clinical Pharmacology & Therapeutics 1996
Rifampin drastically reduces plasma concentrations and effects of oral midazolam
JT Backman, KT Olkkola, PJ Neuvonen
Clinical Pharmacology & Therapeutics 1996
Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine*
CM Stein, MT Kinirons, T Pincus, GR Wilkinson, AJ Wood
Clinical Pharmacology & Therapeutics 1996
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans
EG Schuetz, AH Schinkel, MV Relling, JD Schuetz
Proceedings of the National Academy of Sciences 1996
Influence of clinicopathological variables on CYP protein expression in human liver
J George, K Byth, GC Farrell
Journal of Gastroenterology and Hepatology 1996
Use of Hepatic Lidocaine Metabolism to Monitor Patients with Chronic Liver Disease
ML Shiffman, VA Luketic, AJ Sanyal, EB Thompson
Therapeutic Drug Monitoring 1996
Psychiatry, psychopharmacology and P-450s
P Glue, C Banfield
Human Psychopharmacology: Clinical and Experimental 1996
The use of lidocaine as a test of liver function in liver transplantation
JM Potter, M Oellerich
Liver Transplantation and Surgery 1996
Identification of Human Liver Cytochrome P-450 3A4 as the Enzyme Responsible for Fentanyl and Sufentanil N-Dealkylation
T Tateishi, Y Krivoruk, YF Ueng, AJ Wood, FP Guengerich, M Wood
Anesthesia & Analgesia 1996
The influence of cytochrome P450 enzyme activity on the composition and quantity of volatile organics in expired breath
JM Mathews, JH Raymer, GR Velez, CE Garner, JR Bucher
Biomarkers 1996
The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics*
RZ Harris, SM Tsunoda, P Mroczkowski, H Wong, LZ Benet
Clinical Pharmacology & Therapeutics 1996
Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation*
DR Jones, JC Gorski, BD Haehner, EM O'Mara, SD Hall
Clinical Pharmacology & Therapeutics 1996
Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity
DR Jones, JC Gorski, MA Hamman, SD Hall
Journal of Chromatography B: Biomedical Sciences and Applications 1996
Trimethadione as a probe drug to estimate hepatic oxidizing capacity in humans
E Tanaka, A Ishikawa, M Abei, S Kobayashi
Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology 1996
Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity
J Ducharme, S Abdullah, IW Wainer
Journal of Chromatography B Biomedical Sciences and Applications 1996
Assessment of Doxylamine Influence on Mixed Function Oxidase Activity upon Multiple Dose Oral Administration to Normal Volunteers
GA Thompson, JV st. Peter, MA Heise, ZD Horowitz, GC Salyers, TT Charles, C Brezovic, DA Russell, JA Skare, JH Powell
Journal of Pharmaceutical Sciences 1996
Identification of Human Liver Cytochrome P-450 3A4 as the Enzyme Responsible for Fentanyl and Sufentanil N-Dealkylation:
T Tateishi, Y Krivoruk, YF Ueng, AJ Wood, FP Guengerich, M Wood
Anesthesia & Analgesia 1996
Introduction to Drug Metabolism
GG Gibson, P Skett
1996
The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy:
SM Tsunoda, FT Aweeka
Clinical Pharmacokinetics 1996
Drug Interactions and the Cytochrome P-450 Enzymes
JA Carlston
Pediatric Asthma, Allergy & Immunology 1995
Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test
T Tateishi, SG Graham, Y Krivoruk, AJ Wood
British Journal of Clinical Pharmacology 1995
Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease
J George, M Murray, K Byth, GC Farrell
Hepatology 1995
Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver
J George
Biochemical Pharmacology 1995
The erythromycin breath test predicts the clearance of midazolam*
KS Lown, KE Thummel, PE Benedict, DD Shen, DK Turgeon, S Berent, PB Watkins
Clinical Pharmacology & Therapeutics 1995
Alternative cyclosporine metabolic pathways and toxicity
U Christians, KF Sewing
Clinical Biochemistry 1995
Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test [letter]
T Tateishi, SG Graham, Y Krivoruk, AJ Wood
British Journal of Clinical Pharmacology 1995
The influence of rifampin treatment on caffeine clearance in healthy man
H Wietholtz, T Zysset, HU Marschall, K Generet, S Matern
Journal of Hepatology 1995
The Use of In Vitro Metabolism Techniques in the Planning and Interpretation of Drug Safety Studies
SA Wrighton, BJ Ring, M Vandenbranden
Toxicologic pathology 1995
GENETIC PREDISPOSITION TO DRUG-INDUCED LIVER DISEASE
RJ Fontana, PB Watkins
Gastroenterology Clinics of North America 1995
Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin
A A Somogyi, F Bochner, D Hetzel, D B Williams
Pharmaceutical Research 1995
Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis
ML Shiffman, VA Luketic, AJ Sanyal, PF Duckworth, PP Purdum, MJ Contos, AS Mills, LE Edinboro, A Poklis
Hepatology 1994
Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity
FP Guengerich
Toxicology Letters 1994
Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients
Y Cakaloglu, JM Tredger, J Devlin, R Williams
Hepatology 1994
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
JC Gorski, SD Hall, DR Jones, M VandenBranden
Biochemical Pharmacology 1994
Characterization of dextromethorphan N-demethylation by human liver microsomes
JC Gorski, DR Jones, SA Wrighton, SD Hall
Biochemical Pharmacology 1994
Role of Human Cytochromes P450 in the Metabolic Activation of Chemical Carcinogens and Toxins
FJ Gonzalez, HV Gelboin
Drug Metabolism Reviews 1994
Pharmacokinetic Evaluation of a New Oral Cyclosporine Formulation
JK Whipple, KS Lewis, SD Weitman, RK Ausman, DW Bourne, W Andrews, MB Adams, EA Sasse, EJ Quebbeman
Pharmacotherapy 1994
Augmented arterial pressure responses to cyclosporine in spontaneously hypertensive rats. Role of cytochrome P-450 3A
AK Basu, S Ghosh, PK Mohanty, CO Watlington
Hypertension 1994
Pharmacokinetics of Drugs
PG Welling, LP Balant
1994
Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research
MR Waterman, M Hildebrand
1994
Pharmacogenetic Phenotyping and Genotyping: Present Status and Future Potential
FJ Gonzalez, JR Idle
Clinical Pharmacokinetics 1994
Assessment of Liver Metabolic Function: Clinical Implications
J Brockmöller, I Roots
Clinical Pharmacokinetics 1994
Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase
MS Shet, CW Fisher, PL Holmans, RW Estabrook
Proceedings of the National Academy of Sciences 1993
Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes
EG Schuetz, JD Schuetz, SC Strom, MT Thompson, RA Fisher, DT Molowa, D Li, PS Guzelian
Hepatology 1993
Cyclosporin metabolism in transplant patients
U Christians, KF Sewing
Pharmacology & Therapeutics 1993
Interferon suppresses erythromycin metabolism in rats and human subjects
PI Craig, M Tapner, GC Farrell
Hepatology 1993
Cultured adult rat jejunal explants as a model for studying regulation of CYP3A
P Schmiedlin-Ren, PE Benedict, WO Dobbins, M Ghosh, JC Kolars, PB Watkins
Biochemical Pharmacology 1993
Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions
RP Remmel, B Burchell
Biochemical Pharmacology 1993
The use of in vitro metabolism studies in the understanding of new drugs
SH Chiu
Journal of Pharmacological and Toxicological Methods 1993
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
JC Kolars, P Schmiedlin-Ren, JD Schuetz, C Fang, PB Watkins
Journal of Clinical Investigation 1992
Human cytochrome P-450 enzymes
FP Guengerich
Life Sciences 1992
Immunoquantification of cytochrome P-450 3A on rat paraffin-embedded liver tissue
Y Horsmans, M Stevens, A Geubel, C Harvengt, J Rahier
Liver 1992
Enzyme induction by drugs and toxins
AM Batt, G Siest, J Magdalou, MM Galteau
Clinica Chimica Acta 1992
Human cytochromes P450: problems and prospects
FJ Gonzalez
Trends in Pharmacological Sciences 1992
Absence of CYP3 A Genetic Polymorphism Assessed by Urinary Excretion of 6 β-Hydroxycortisol in 102 Healthy Subjects on Rifampicin
Y Horsmans, JP Desager, C Harvengt
Pharmacology & Toxicology 1992
Effect of age and gender on the activity of human hepatic CYP3A
CM Hunt, WR Westerkam, GM Stave
Biochemical Pharmacology 1992
The Human Hepatic Cytochromes P450 Involved in Drug Metabolism
SA Wrighton, JC Stevens
Critical Reviews in Toxicology 1992
Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia
JC Kolars, P Schmiedlin-Ren, WO Dobbins, J Schuetz, SA Wrighton, PB Watkins
Gastroenterology 1992
Hepatic cytochrome P-4503A (CYP3A) activity in the elderly
CM Hunt, WR Westerkam, GM Stave, JA Wilson
Mechanisms of Ageing and Development 1992
DRUG METABOLISM BY CYTOCHROMES P450 IN THE LIVER AND SMALL BOWEL
PB Watkins
Gastroenterology Clinics of North America 1992
P450 Enzymes: Inhibition Mechanisms, Genetic Regulation and Effects of Liver Disease
M Murray
Clinical Pharmacokinetics 1992
The functioning liver mass
G Molino
La Ricerca in Clinica e in Laboratorio 1991
Role of human hepatic cytochromes P450 in drug metabolism and toxicity
J George, GC Farrell
Australian and New Zealand Journal of Medicine 1991
Utilization of labeled Escherichia coli as phospholipase substrate
P Elsbach, J Weiss
Methods in enzymology 1991
Prediction of Xenobiotic Metabolism by Non-Invasive Methods
S Loft, HE Poulsen
Pharmacology & Toxicology 1990
Differential regulation of liver P-450III cytochromes in choline-deficient rats: Implications for the erythromycin breath test as a parameter of liver function
JC Kolars, SA Murray, KM Peters, PB Watkins
Hepatology 1990
Metabolism of 17 α-ethynylestradiol in humans
FP Guengerich
Life Sciences 1990
Expression of cytochrome P-450 enzymes in cultured human hepatocytes
F MOREL, PH BEAUNE, D RATANASAVANH, JP FLINOIS, CS YANG, FP GUENGERICH, A GUILLOUZO
European Journal of Biochemistry 1990
Substrate specificities and functions of the P450 cytochromes
MR Juchau
Life Sciences 1990
The role of cytochromes P-450 in cyclosporine metabolism
PB Watkins
Journal of the American Academy of Dermatology 1990
Distribution of cytochromes P-450, cytochrome b5, and nadph-cytochrome P-450 reductase in an entire human liver
PB Watkins, SA Murray, PE Thomas, SA Wrighton
Biochemical Pharmacology 1990
Hormonal Regulation of Male-specific Rat Hepatic Cytochrome P-450g (P-450IIC13) by Androgens and the Pituitary
PD McClellan-Green, P Linko, HN Yeowell, JA Goldstein
The Journal of biological chemistry 1989

← Previous 1 2 3 … 11 12 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 12 patents
35 readers on Mendeley
See more details